Table 1 KEGG Pathway Enrichment
From: Prediction of HIV-1 virus-host protein interactions using virus and host sequence motifs
| Â | ENV HHP | ENV HHE | NEF HHP | NEF HHE | TAT HHP | TAT HHE |
|---|---|---|---|---|---|---|
AML | 1.97E-05 | 2.68E-05 | 2.07E-05 | 8.55E-05 | 2.66E-08 | 3.08E-04 |
Adherens junction | 2.15E-09 | NA | 8.21E-11 | NA | 6.74E-06 | NA |
Apoptosis | 4.58E-04 | 1.43E-13 | 5.18E-04 | 6.54E-04 | 3.91E-03 | 3.88E-13 |
B cell receptor signaling pathway | 4.86E-06 | 8.73E-10 | 2.88E-04 | 2.90E-04 | 1.25E-09 | 5.57E-06 |
Cell cycle | NA | NA | NA | NA | 2.88E-04 | 1.90E-01 |
CML | 7.21E-05 | 2.23E-05 | 1.17E-06 | 2.46E-05 | 1.01E-09 | 7.53E-07 |
Colorectal cancer | 1.07E-05 | 3.18E-04 | 4.68E-08 | 3.31E-03 | 4.50E-04 | 1.42E-03 |
Endometrial cancer | 6.03E-04 | 1.62E-02 | 1.66E-04 | 2.10E-03 | 5.03E-07 | 3.83E-04 |
Epithelial cell signaling in H. pylori infection | 2.29E-04 | 3.84E-06 | 2.07E-06 | 2.83E-05 | NA | NA |
ErbB signaling | 2.27E-10 | 5.70E-04 | 1.70E-12 | 9.22E-04 | 1.53E-12 | 1.66E-05 |
Fc epsilon RI signaling pathway | 8.43E-04 | 6.23E-21 | 2.14E-05 | 2.20E-07 | 9.62E-05 | 1.52E-04 |
Focal adhesion | 2.82E-06 | 2.30E-03 | 2.31E-07 | 6.90E-02 | 5.28E-08 | 3.36E-09 |
Gap junction | 1.90E-04 | 1.26E-04 | NA | NA | 1.12E-04 | 7.18E-10 |
Glioma | 1.50E-04 | 1.24E-05 | 4.99E-06 | 6.02E-03 | 1.56E-07 | 6.79E-11 |
Insulin signaling | 1.53E-07 | 8.84E-02 | 1.73E-04 | 3.50E-01 | 2.91E-07 | 7.35E-02 |
Jak-STAT signaling | 4.08E-08 | 2.15E-04 | 4.09E-09 | 1.28E-01 | 2.32E-17 | 4.91E-03 |
Leukocyte transendothelial migration | 1.94E-07 | 2.21E-08 | 1.17E-08 | 6.36E-01 | 3.28E-05 | 1.45E-01 |
Long-term potentiation | 6.79E-05 | 2.20E-02 | NA | NA | 9.04E-03 | 2.38E-10 |
MAPK signaling | 5.19E-08 | 6.32E-04 | 1.58E-09 | 3.27E-03 | 1.18E-03 | 5.15E-01 |
NK cell mediated cytotoxicity | NA | NA | NA | NA | 9.50E-06 | 5.31E-15 |
Non-small cell lung cancer | 4.28E-05 | 1.25E-04 | 1.26E-05 | 1.67E-03 | 7.55E-06 | 1.45E-06 |
Pancreatic cancer | 1.26E-04 | 5.54E-07 | 1.10E-05 | 2.50E-06 | 1.03E-05 | 8.15E-08 |
Pathogenic E. coli infection – EHEC | 3.77E-03 | 1.00E+00 | 2.94E-03 | NA | 9.74E-03 | 3.25E-01 |
Phosphatidylinositol signaling system | 1.36E-03 | 1.72E-04 | 2.37E-03 | NA | 2.19E-05 | 9.74E-06 |
Prostate cancer | 1.90E-04 | 1.26E-04 | 6.26E-06 | 6.56E-05 | 5.46E-09 | 1.11E-07 |
Regulation of actin cytoskeleton | 4.30E-03 | 6.02E-01 | 1.73E-03 | 8.79E-01 | 2.66E-03 | 7.65E-01 |
Small cell lung cancer | 1.94E-03 | 3.71E-10 | 8.42E-05 | 4.25E-02 | 1.12E-04 | 4.09E-14 |
T cell receptor signaling pathway | NA | NA | NA | NA | 1.56E-06 | 1.35E-11 |
Tight junction | 1.24E-03 | 1.00E+00 | 5.29E-04 | NA | NA | NA |
Toll-like receptor signaling pathway | 5.16E-03 | 2.04E-14 | 5.37E-05 | 2.04E-14 | NA | NA |
Type II diabetes mellitus | NA | NA | NA | NA | 3.47E-03 | 5.95E-01 |
VEGF signaling | 3.23E-03 | 4.89E-15 | 6.79E-03 | 8.82E-03 | 1.88E-05 | 4.07E-12 |